CCEL.AMEXCryo Cell International INC

Form 4: Cryo-Cell Director Acquires New Stock Options

Sentiment:

Insider Transaction Report

📋All filings for Cryo Cell International INC
🔒Login to Follow

Cryo-Cell International Director Harold D. Berger acquired 5,300 new stock options with an exercise price of $4.35, exercisable on October 21, 2025.

Summary

  • Harold D. Berger, a Director of Cryo-Cell International Inc. (CCEL), reported changes in beneficial ownership.
  • On October 21, 2025, Mr. Berger acquired 5,300 stock options.
  • These newly acquired options have an exercise price of $4.35 per share.
  • The options become exercisable on October 21, 2025, and expire on October 21, 2035.
  • Following this transaction, Mr. Berger directly owns 57,901 shares of common stock.
  • Mr. Berger's total beneficial ownership of derivative securities (stock options) is 44,600.
  • The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: A director's acquisition of stock options, particularly under a Rule 10b5-1 plan, generally signals confidence in the company's long-term prospects and aligns management incentives with shareholder interests.

Positives

  • Director Harold D. Berger acquired 5,300 new stock options, which can be interpreted as a signal of continued confidence in the company's long-term prospects.
  • The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned and systematic approach to equity transactions, which can reduce concerns about opportunistic insider trading.

Future Outlook

The acquisition of stock options with an expiration date in 2035 suggests a long-term perspective on the company's future performance by a director.

Management Comments

  • Harold D. Berger, a Director, reported an acquisition of stock options, indicating a pre-planned equity transaction under a Rule 10b5-1 plan.

Industry Context

This filing is specific to insider transactions at Cryo-Cell International and does not directly provide broader industry context.

Stakeholder Impact

  • Shareholders may view the director's acquisition of stock options as a positive signal of confidence in the company's future.

Key Dates

DateDescription
08/30/2019Grant date for 7,500 stock options with an exercise price of $7.53.
11/25/2019Grant date for 5,300 stock options with an exercise price of $7.74.
09/22/2020Grant date for 5,300 stock options with an exercise price of $7.85.
10/20/2021Grant date for 5,300 stock options with an exercise price of $12.63.
10/03/2022Grant date for 5,300 stock options with an exercise price of $6.50.
10/10/2023Grant date for 5,300 stock options with an exercise price of $4.90.
10/29/2024Grant date for 5,300 stock options with an exercise price of $5.82.
10/21/2025Transaction date for the acquisition of 5,300 stock options with an exercise price of $4.35; also the date these options become exercisable.
10/23/2025Signature date of the reporting person, Harold D. Berger.
08/30/2029Expiration date for 7,500 stock options.
11/25/2029Expiration date for 5,300 stock options.
09/22/2030Expiration date for 5,300 stock options.
10/20/2031Expiration date for 5,300 stock options.
10/03/2032Expiration date for 5,300 stock options.
10/10/2033Expiration date for 5,300 stock options.
10/29/2034Expiration date for 5,300 stock options.
10/21/2035Expiration date for the newly acquired 5,300 stock options.

Recommendation

hold

The director's acquisition of stock options, while a positive signal of confidence, is a routine insider transaction under a Rule 10b5-1 plan and does not provide sufficient new information to alter a fundamental investment thesis. It reinforces a 'hold' position for existing investors.

Keywords

Cryo-Cell International, CCEL, stock options, insider transaction, Form 4, director, beneficial ownership, Harold Berger, equity acquisition, Rule 10b5-1

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.